Brian Park, PharmD

Drug Information Specialist https://www.rheumatologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Rheumatoid Arthritis

Biosimilar Rituximab-Arrx Approved for Rheumatoid Arthritis

Brian Park, PharmD

June 13, 2022

The approval is supported by data from a phase 3 study that compared the efficacy, safety, pharmacokinetics and immunogenicity of Riabni to rituximab reference products.

General Rheumatology

Gentamicin-Eluting Bone Graft Substitute Gets FDA Clearance

Brian Park, PharmD

May 25, 2022

Cerament G is a resorbable, gentamicin-eluting ceramic bone void filler.

General Medicine

FDA Declines EUA Request for Fluvoxamine for COVID-19 Treatment

Brian Park, PharmD

May 24, 2022

The totality of the evidence led the FDA to determine that the criteria for issuing an EUA had not been met.

General Medicine

Pfizer-BioNTech COVID-19 Vaccine Booster Dose Authorized for 5- to 11-Year-Olds

Brian Park, PharmD

May 19, 2022

The Pfizer-BioNTech COVID-19 vaccine can be administered as a single booster dose to individuals 5 to 11 years of age at least 5 months after completion of the primary series.

General Medicine

Remdesivir Approval Expanded to Include COVID-19 Treatment in Younger Children

Brian Park, PharmD

May 18, 2022

The approval was supported by data from a phase 2/3 CARAVAN study.

General Medicine

Online Pharmacies Warned for Illegally Selling Schedule II Stimulants

Brian Park, PharmD

May 16, 2022

The FDA urges consumers to buy prescription drugs, such as Adderall, from state-licensed US pharmacies or physicians located in the US.

coronavirus disease 2019 covid lungs illustration

General Medicine

Baricitinib Approved for COVID-19 Treatment in Hospitalized Adults

Brian Park, PharmD

May 13, 2022

The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.

Ankylosing Spondylitis

Upadacitinib Approved for Active Ankylosing Spondylitis

Brian Park, PharmD

May 6, 2022

The approval was based on data from the phase 2/3 SELECT-AXIS 1 and the phase 3 SELECT-AXIS 2 trials.

General Medicine

USPSTF Issues Recommendations on Aspirin Use to Prevent Cardiovascular Disease

Brian Park, PharmD

May 4, 2022

These recommendations only apply to individuals who do not have a history of CVD and are not already taking daily aspirin.

General Medicine

FDA Authorizes Shelf-Life Extension for Certain COVID-19 Vaccines

Brian Park, PharmD

April 28, 2022

The FDA has extended shelf-life for the Janssen COVID-19 vaccine and the Pfizer-BioNTech COVID-19 vaccine following a thorough review of data submitted by both manufacturers.

Next post in General Medicine